object
studi
compar
infusionrel
reaction
outcom
use
subcutan
subq
alemtuzumab
versu
intraven
iv
alemtuzumab
graftversushost
diseas
gvhd
prophylaxi
match
unrel
donor
stem
cell
transplant
outcom
includ
incid
cytomegaloviru
cmv
epsteinbarr
ebv
viremia
develop
cmv
diseas
posttransplant
lymphoprolif
disord
fatal
infect
acut
chronic
gvhd
time
engraft
relaps
rate
surviv
conduct
retrospect
studi
adult
match
unrel
donor
stem
cell
transplant
patient
receiv
fludarabinemelphalan
subq
iv
alemtuzumab
combin
tacrolimu
part
condit
unrel
donor
transplant
new
yorkpresbyterianweil
cornel
medic
center
januari
march
alemtuzumab
administ
total
cumul
dose
mg
divid
day
fortysix
patient
receiv
unrel
donor
stem
cell
transplant
fludarabinemelphalan
either
subq
n
iv
n
alemtuzumab
combin
tacrolimu
within
evalu
popul
subq
iv
alemtuzumab
dose
administ
primari
outcom
grade
infusionrel
reaction
occur
versu
infus
subq
iv
cohort
respect
p
overal
inject
subq
arm
versu
infus
iv
arm
experienc
infusionrel
reaction
grade
p
signific
differ
subq
iv
arm
rate
reactiv
cmvebv
develop
cmv
diseas
posttransplant
lymphoprolif
disord
fatal
infect
acut
chronic
gvhd
relaps
surviv
subcutan
administr
alemtuzumab
gvhd
prophylaxi
associ
fewer
infusionrel
reaction
compar
iv
administr
sct
set
incid
acut
chronic
gvhd
similar
arm
also
differ
reactiv
cmvebv
viremia
develop
cmv
diseas
posttransplant
lymphoprolif
disord
fatal
infect
relaps
surviv
allogen
stem
cell
transplant
import
treatment
option
variou
malign
nonmalign
condit
howev
graftversushost
diseas
gvhd
remain
major
caus
posttransplant
morbid
mortal
alemtuzumab
human
monoclon
antibodi
target
antigen
express
surfac
b
lymphocyt
monocyt
eosinophil
macrophag
dendrit
cell
hematopoiet
progenitor
cell
base
previous
publish
data
alemtuzumabcontain
regimen
allogen
stem
cell
transplant
shown
substanti
benefit
reduc
acut
particularli
chronic
gvhd
surviv
rate
compar
similar
regimen
convent
gvhd
prophylaxi
mani
center
includ
adopt
alemtuzumab
part
standard
transplant
gvhd
prophylaxi
howev
intraven
iv
administr
biolog
blood
marrow
transplant
j
u
r
n
l
h
e
p
g
e
w
w
w
b
b
r
g
alemtuzumab
commonli
accompani
infusionrel
side
effect
rang
anywher
local
inject
site
reaction
anaphylaxi
subcutan
subq
rout
administr
shown
reduc
incid
infusionrel
reaction
without
decreas
efficaci
use
chronic
lymphocyt
leukemia
use
compar
adult
stem
cell
transplant
earli
introduc
routin
use
subq
alemtuzumab
unrel
donor
transplant
patient
goal
current
studi
compar
side
effect
profil
efficaci
subq
versu
iv
alemtuzumab
unrel
donor
stem
cell
transplant
institut
review
boardeapprov
retrospect
cohort
studi
conduct
new
yorkpresbyterian
weill
cornel
medic
center
includ
adult
patient
year
age
undergo
unrel
donor
transplant
use
fludarabinemelphalanalemtuzumab
condit
januari
march
patient
receiv
fludarabin
mgm
day
iv
day
day
melphalan
mgm
day
day
gvhd
prophylaxi
patient
receiv
alemtuzumab
mg
day
iv
hour
subq
consecut
day
day
tacrolimu
start
day
routin
continu
day
unless
patient
develop
gvhd
figur
alemtuzumab
subq
formul
administ
undilut
drug
avail
mgml
vial
dose
tacrolimu
target
trough
level
maintain
ngml
ngml
case
tacrolimu
replac
either
mycophenol
mofetil
sirolimu
patient
intoler
patient
develop
gvhd
immunosuppress
adjust
clinic
requir
acetaminophen
mg
diphenhydramin
mg
given
prevent
infusionrel
reaction
alemtuzumab
addit
iv
cohort
methylprednisolon
mgkg
given
alemtuzumab
follow
mgkg
halfway
infus
day
infus
patient
subq
cohort
receiv
hydrocortison
mg
alemtuzumab
antiinfect
prophylaxi
includ
levofloxacin
mg
daili
engraft
fluconazol
mg
daili
voriconazol
mg
twice
daili
patient
immunosuppress
medic
sulfamethoxazoletrimethoprim
doublestrength
tablet
twice
daili
admiss
day
day
transplant
patient
resum
pneumocysti
pneumonia
prophylaxi
preemptiv
cytomegaloviru
cmv
treatment
cmv
igg
seroposit
donor
andor
recipi
patient
receiv
ganciclovir
mgkg
iv
twice
daili
day
admiss
day
acyclovir
mgm
year
old
mgm
year
old
everi
hour
iv
day
engraft
follow
highdos
oral
valacyclovir
g
year
old
g
year
old
time
daili
day
day
patient
receiv
valacyclovir
mg
oral
twice
daili
continu
minimum
year
stem
cell
transplant
longer
patient
continu
immunosuppress
medic
cmvigg
seroneg
donor
recipi
patient
receiv
oral
valacyclovir
mg
twice
daili
start
day
continu
minimum
year
stem
cell
transplant
longer
patient
remain
immunosuppress
medic
patient
receiv
filgrastim
start
day
transplant
case
day
transfus
support
administ
indic
per
institut
polici
pack
red
blood
cell
hemoglobin
gramsdl
platelet
primari
outcom
incid
grade
infusionrel
reaction
within
hour
subq
iv
alemtuzumab
dose
infusionrel
reaction
defin
local
inject
site
reaction
swellingerythema
fever
defin
c
chillsrigor
rashurticaria
hypotens
bronchospasmsdyspnea
anaphylaxi
grade
infusionrel
reaction
well
hypotens
determin
use
common
terminolog
criteria
advers
eventscanc
therapi
evalu
program
criteria
tabl
secondari
outcom
includ
incid
cmv
viremia
diseas
epsteinbarr
ebv
viremia
posttransplant
lymphoprolif
disord
fatal
infect
relaps
rate
overal
surviv
first
year
time
neutrophil
platelet
engraft
incid
acut
chronic
gvhd
also
analyz
cmv
viremia
defin
first
posit
polymeras
chain
reaction
pcr
copiesml
cmv
diseas
defin
presenc
cmv
viremia
organ
involv
pneumonia
retin
coliti
marrow
involv
week
initi
treatment
recurr
cmv
viremia
defin
cmv
viremia
occur
consecut
neg
real
time
pcr
assay
treatment
initi
episod
infect
requir
empir
treatment
ebv
viremia
also
record
first
posit
pcr
copiesml
diagnosi
posttransplant
lymphoprolif
disord
base
positron
emiss
tomographi
scan
tissu
biopsi
neutrophil
engraft
defin
first
day
absolut
neutrophil
count
l
platelet
engraft
defin
first
consecut
day
platelet
count
l
maintain
without
transfus
support
consecut
day
acut
gvhd
assess
grade
base
consensu
confer
acut
gvhd
grade
assess
grade
chronic
gvhd
base
nation
institut
health
consensu
develop
project
criteria
clinic
trial
chronic
gvhd
fisher
exact
chisquar
test
use
compar
categor
variabl
group
mannwhitney
test
use
compar
continu
variabl
group
comparison
type
error
estim
group
report
along
confid
interv
breslowgehanwilcoxon
test
use
compar
timerel
measur
group
fortysix
consecut
patient
receiv
unrel
donor
stem
cell
transplant
fludarabinemelphalanbas
condit
either
subq
iv
alemtuzumab
combin
tacrolimu
gvhd
prophylaxi
twentysix
patient
receiv
subq
alemtuzumab
receiv
iv
alemtuzumab
overal
subq
dose
iv
alemtuzumab
dose
administ
treatment
group
balanc
respect
age
gender
diseas
state
tabl
diseas
statu
transplant
graft
sourc
differ
group
notabl
subq
group
patient
stabl
diseas
patient
subq
group
receiv
peripher
blood
stem
cell
transplant
wherea
iv
group
stem
cell
deriv
bone
marrow
karnofski
perform
statu
time
transplant
similar
treatment
group
differ
sorror
comorbid
score
american
societi
blood
marrow
transplant
risk
categori
group
p
infusionrel
reaction
grade
higher
occur
versu
infus
subq
iv
cohort
p
overal
inject
subq
arm
versu
infus
iv
arm
result
grade
infusionrel
reaction
p
hypotens
grade
seen
inject
subq
arm
infus
iv
arm
p
tabl
reaction
occur
infus
stop
rescu
medic
given
requir
infus
resum
slower
rate
patient
delay
miss
dose
minor
local
site
reaction
common
subq
inject
grade
reaction
occur
signific
differ
subq
iv
alemtuzumab
infecti
complic
outcom
cmv
viremia
occur
patient
subq
arm
patient
iv
arm
p
howev
cmv
diseas
occur
patient
iv
arm
median
time
cmv
viremia
also
similar
subq
arm
versu
iv
arm
versu
day
p
ebv
viremia
occur
patient
subq
arm
patient
iv
arm
p
median
time
ebv
viremia
significantli
shorter
subq
arm
iv
arm
versu
day
p
respect
patient
subq
group
develop
posttransplant
lymphoprolif
disord
death
due
fatal
infect
occur
patient
subq
arm
patient
iv
arm
fatal
infect
includ
e
coli
bacteremia
concomit
coronaviru
subq
arm
viridan
group
streptococcu
bacteremia
vancomycinresist
enterococcu
bacteremia
iv
arm
differ
time
engraft
neutrophil
arm
howev
median
time
platelet
engraft
shorter
subq
cohort
iv
cohort
day
versu
day
p
iv
cohort
patient
engraft
neutrophil
platelet
patient
recov
platelet
caus
death
patient
includ
relaps
n
multiorgan
failur
n
bacteremia
n
complic
engraft
failur
n
subq
arm
patient
engraft
neutrophil
platelet
caus
death
patient
sepsi
evalu
patient
assess
lymphocyt
reconstitut
day
median
lymphocyt
count
day
ident
subq
iv
cohort
cellsml
mix
chimer
defin
less
donor
chimer
common
alemtuzumabbas
condit
found
differ
group
iv
group
patient
donor
cell
donor
cell
day
respect
subq
group
patient
donor
cell
donor
cell
day
respect
acut
gvhd
grade
seen
patient
subq
arm
patient
iv
arm
p
organ
affect
acut
gvhd
includ
gastrointestin
tract
skin
median
time
onset
acut
gvhd
seem
shorter
subq
arm
iv
arm
day
versu
day
differ
statist
signific
p
chronic
gvhd
occur
small
number
patient
group
patient
either
group
develop
sever
chronic
gvhd
median
time
chronic
gvhd
also
similar
group
versu
day
p
tabl
differ
number
patient
relaps
time
relaps
cohort
tabl
patient
relaps
iv
group
patient
die
progress
diseas
subq
group
relaps
patient
die
progress
diseas
differ
mortal
overal
surviv
subq
iv
group
versu
p
signific
versu
p
signific
caus
death
iv
arm
includ
relaps
n
fatal
infect
n
multiorgan
failur
n
complic
graft
failur
n
caus
death
subq
arm
includ
relaps
n
pneumonia
n
posttransplant
lymphoprolif
disord
n
acut
respiratori
distress
syndrom
n
fatal
infect
n
year
thousand
patient
hematolog
malign
undergo
allogen
stem
cell
transplant
offer
chanc
cure
acut
chronic
gvhd
often
sever
sometim
debilit
potenti
deadli
complic
transplant
alemtuzumab
use
success
prevent
gvhd
allogen
stem
cell
transplant
posit
longterm
outcom
except
recent
data
pediatr
patient
underw
transplant
nonmalign
diseas
state
iv
rout
administr
alemtuzumab
use
stem
cell
transplant
howev
iv
alemtuzumab
associ
seriou
infusionrel
reaction
includ
fever
chill
rigor
rash
hypotens
short
breath
bronchospasm
anaphylaxi
prevent
reaction
requir
pretreat
antihistamin
corticosteroid
antipyret
report
institut
experi
patient
approxim
period
data
present
n
unless
otherwis
indic
fever
c
chillsrigor
anaphylaxi
rashurticaria
hypotens
bronchospasmsdyspnea
local
inject
site
reaction
swellingerythema
ptld
indic
posttransplant
lymphoprolif
disord
data
present
n
unless
otherwis
indic
one
patient
subcutan
arm
patient
intraven
arm
defin
receiv
iv
receiv
subq
alemtuzumab
found
significantli
lower
rate
grade
infusionrel
reaction
subq
administr
compar
iv
rout
versu
p
respect
outcom
group
patient
remark
similar
incid
acut
chronic
gvhd
similar
subq
iv
arm
indic
subq
alemtuzumab
may
similar
efficaci
iv
alemtuzumab
prevent
gvhd
patient
subq
arm
experienc
grade
acut
gvhd
patient
experienc
sever
chronic
gvhd
consist
studi
iv
alemtuzumabcontain
regimen
observ
incid
acut
gvhd
low
incid
sever
chronic
gvhd
also
observ
differ
risk
diseas
recurr
notic
increas
incid
cmv
ebv
reactiv
number
infectionrel
death
due
bacteri
infect
significantli
differ
patient
given
subq
versu
iv
alemtuzumab
lastli
differ
mortal
overal
surviv
transplant
treatment
group
consist
result
subq
administr
alemtuzumab
shown
reduc
incid
infusionrel
reaction
maintain
efficaci
use
treatment
chronic
lymphocyt
leukemia
lundin
et
al
conduct
phase
ii
openlabel
studi
determin
efficaci
safeti
alemtuzumab
deliv
subq
firstlin
therapi
prolong
treatment
period
week
patient
symptomat
b
cell
chronic
lymphocyt
leukemia
n
day
mg
alemtuzumab
administ
subq
inject
well
toler
dose
rais
mg
day
rais
target
dose
mg
split
inject
site
ml
site
day
mg
dose
given
time
weekli
maximum
week
prophylact
medic
firstdos
reaction
includ
antipyret
antihistamin
given
minut
inject
first
dose
reaction
frequent
seen
iv
administr
alemtuzumab
rare
absent
studi
transient
rigor
seen
patient
fever
observ
patient
inject
site
reaction
seen
patient
episod
rashurticaria
bronchospasm
hypotens
appear
subq
administr
induc
local
inject
site
reaction
instead
flulik
symptom
iv
administr
given
rel
urgenc
compress
time
frame
transplant
condit
regimen
success
omit
initi
dose
rampup
subq
iv
alemtuzumab
without
excess
incid
reaction
contrast
subq
alemtuzumab
use
treatment
cell
prolymphocyt
leukemia
efficaci
appear
diminish
cautionari
observ
underscor
need
studi
pharmacokinet
biodistribut
alemtuzumab
may
differ
accord
diseas
remiss
statu
rout
administr
pharmacokinet
studi
undertaken
patient
chronic
lymphocyt
leukemia
clear
peak
level
antibodi
obtain
iv
subq
administr
alemtuzumab
howev
pharmacokinet
studi
need
conduct
fulli
understand
util
obtain
mean
serum
level
subq
administr
alemtuzumab
set
includ
bone
marrow
transplant
analysi
limit
despit
studi
design
minim
confound
variabl
data
collect
retrospect
therefor
subject
usual
restrict
bia
type
analysi
howev
microbiolog
laboratori
data
collect
use
electron
medic
record
minim
absent
data
underreport
rel
small
sampl
size
also
make
difficult
obtain
statist
signific
secondari
endpoint
howev
primari
aim
report
differ
infusionrel
reaction
subq
iv
administr
alemtuzumab
shown
statist
signific
consist
current
literatur
publish
chronic
lymphocyt
leukemia
analysi
also
limit
patient
receiv
match
unrel
allogen
stem
cell
transplant
larger
studi
need
assess
role
subq
alemtuzumab
transplant
type
well
pharmacokinet
differ
iv
subq
administr
primari
focu
studi
differ
graft
sourc
iv
subq
cohort
patient
subq
arm
receiv
peripher
blood
stem
cell
patient
iv
cohort
receiv
bone
marrow
stem
cell
howev
result
statist
signific
increas
incid
gvhd
subq
cohort
analysi
engraft
limit
differ
graft
sourc
continu
use
subq
alemtuzumab
monitor
data
longterm
followup
period
need
assess
outcom
overal
surviv
chronic
gvhd
conclus
studi
albeit
retrospect
repres
first
direct
compar
analysi
subq
versu
iv
alemtuzumab
adult
stem
cell
transplant
patient
hematolog
malign
signific
differ
infecti
complic
relaps
gvhd
surviv
found
group
except
shorter
median
time
ebv
viremia
platelet
engraft
subq
arm
transplant
center
util
iv
alemtuzumab
gvhd
prophylaxi
may
consid
transit
subq
alemtuzumab
subq
administr
may
lower
infusionrel
reaction
compar
iv
administr
without
jeopard
efficaci
reduc
gvhd
